Technology Appraisal Virtual Committee Meeting

Committee A

Zoom

## Minutes: Confirmed

## Date and Time: Tuesday 13 October 2020, 09:00am - 5:50pm

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brian Shine (Vice Chair) Present for all notes
3. Mr Richard Ballerand Present for all notes
4. Dr Andrew Champion Present for all notes
5. Dr Justin Daniels Present for all notes
6. Dr Steve Edwards Present for notes 1 to 13
7. Dr Rita Faria Present for notes 9 to 19
8. Dr Khalida Ismail Present for all notes
9. Ms Sumithra Maheswaran Present for all notes
10. Professor G.J. Melendez-Torres Present for notes 1 to 8 & 14 to 19
11. Ugochi Nwulu Present for notes 9 to 19
12. Mrs Stella O’Brien Present for notes 1 to 8
13. Ms Pamela Rees Present for all notes
14. Mr Stephen Sharp Present for all notes
15. Dr Alice Turner Present for all notes
16. Dr Min Ven Teo Present for notes 1 to 13
17. Dr Roger Whittaker Present for notes 1 to 10.3 & 13 to 19
18. Mr Tony Wootton Present for all notes

### In attendance:

* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Jeremy Powell, Project Manager, NICE, Present for notes 9 to 13
* Mira Patel, Administrator, NICE, Present for notes 9 to 13
* Laura Marsden, Coordinator, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, NICE, Present for all notes
* Sophie McHugh, Administrator, NICE, Present for all notes
* Gemma Smith, Coordinator, NICE, Present for all notes
* Sana Khan, Technical Analyst, NICE, Present for notes 1 to 8
* Rufaro Kausi, Technical Adviser, NICE, Present for notes 1 to 8
* Farhaan Jamadar, Technical Analyst, NICE, Present for notes 9 to 13
* Eleanor Donegan, Technical Adviser, NICE, Present for notes 9 to 13
* Marcela Haasova, Technical Analyst, NICE, Present for notes 14 to 19
* Joanna Richardson, Technical Adviser, NICE, Present for notes 14 to 19
* Rita Faria, York CfR & CfHE, Evidence Review Group, Present for notes 1 to 4
* Alison Eastwood, York CfR & CfHE, Evidence Review Group, Present for notes 1 to 4
* Georgios Nikolaidis, York CfR & CfHE, Evidence Review Group, Present for notes 1 to 4
* Peter Murphy, York CfR & CfHE, Evidence Review Group, Present for notes 1 to 4
* Alexis Llewellyn, York CfR & CfHE, Evidence Review Group, Present for notes 1 to 4
* Dina Jankovic, York CfR & CfHE, Evidence Review Group, Present for notes 1 to 4
* Maxwell Barnish, PenTAG, Evidence Review Group, Present for notes 9 to 10
* G.J. Melendez-Torres, PenTAG, Evidence Review Group, Present for notes 9 to 10
* Ash Bullement, PenTAG, Evidence Review Group, Present for notes 9 to 10
* Steve Edwards, BMJ-TAG, Evidence Review Group, Present for notes 14 to 15
* Tracey Jhita, BMJ-TAG, Evidence Review Group, Present for notes 14 to 15
* Victoria Wakefield, BMJ-TAG, Evidence Review Group, Present for notes 14 to 15
* Prof. Andrew Davies, Clinical Expert, Professor of Haematological Malignancies and Consultant Oncologist, Present for notes 1 to 4
* Dr Toby Eyre, Clinical Expert, Consultant Haematologist, Present for notes 1 to 4
* Peter English, Patient Expert, Present for notes 1 to 4
* Stephen Scowcroft, Patient Expert, Director of Operations & External Affairs Lymphoma Action, Present for notes 1 to 4
* Mr John Whiting, Clinical Expert, Consultant Upper GI Surgeon, Present for notes 9 to 10
* Dr Elizabeth Smyth, Clinical Expert, Consultant Oncologist, Present for notes 9 to 10
* Dr Ruth Plummer, Clinical Expert, Clinical Professor of Experimental Cancer Medicine, Honorary Consultant Medical Oncologist, Present for notes 14 to 15
* Prof Peter Clark, Clinical Expert, Cancer Drugs Fund Clinical Lead, Present for all notes

### Non-public attendees:

* Emilene Coventry, Editor, NICE, Present for 1 to 8
* Hayley Garnett, Editor, NICE, Present for notes 14 to 19
* Claire Hawksworth, Managed Access Team, NICE, Present for notes 9 to 13
* Amy Hussain, NIHR Observer, Present for notes 1 to 4, 9 to 10 and 14 to 15
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 4
* Ella Livingstone, Commercial Liaison, NICE, Present for notes 1 to 8 and 14 to 19
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for notes 14 to 15
* Emily Robertson, NIHR Observer, Present for notes 1 to 4, 9 to 10 and 14 to 15
* Ria Skelton, Editor, NICE, Present for notes 9 to 13
* Thomas Strong, Managed Access Team, NICE, Present for notes 1 to 8

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 8 September 2020.

## Appraisal of KTE-X19 for treating relapsed or refractory mantle cell lymphoma [ID1313]

### Part 1 – Closed session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Kite, a Gilead company. The Chair explained that the discussion was being held in a closed session because KTE-X19 had not yet received a CHMP opinion in this indication.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests  
   1. Prof Andrew Davies declared an direct financial interest as he has received payment from Gilead for participation in a novel agent (tirabrutinib and entosplentinib) early phase trial for which he is the Principal Investigator at site. This is unrelated to KTE-X19. He has also received payment from Gilead in July 2019 to judge a Fellowship grant award programme that they funded, this is not related to product under discussion.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   2. Dr Toby Eyre declared a direct financial interest as he has received honorarium from Gilead and research support, plus funding to travel to scientific conferences. He has sat on advisory boards for KITE. He also declared indirect financial interests as he has sat on advisory boards and received honorarium for travel to conferences from comparator and potential competitor companies.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   3. Stephen Scowcroft declared an indirect professional financial interest as he is employed by Lymphoma Action who receive financial support from a range of pharmaceutical companies, including Kite, for their work programme.
      1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
   4. No further conflicts of interest were declared for this appraisal.
   5. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
   6. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
3. The committee decision was based on consensus.

1. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

### Part 2 – Closed session

1. The Chair welcomed the invited clinical, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Bristol-Myers Squibb (nivolumab). The Chair explained that the discussion was being held in a closed session because nivolumab had not yet received a CHMP opinion in this indication.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. Dr Elizabeth Smith declared a direct financial interest as she has previously been compensated for advisory role or educational lectures by comparator and potential competitor companies. She has also received honorarium for travel to conferences from comparator and potential competitor companies.
      1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
   2. No further conflicts of interest were declared for this appraisal.
   3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
   4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts, ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease [ID1681]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Bristol-Myers Squibb
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests  
   1. Dr Ruth Plummer declared a direct financial interest as she is a member of BMS IO academy and has received honorarium for developing educational materials for this.
      1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
   2. No further conflicts of interest were declared for this appraisal.
   3. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
   4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.